+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.

Age: 18Years +All Genders
93 locations
R

Actively Recruiting

Researchers are monitoring the clinical performance and short-term safety of Resorbable Magnesium Scaffolds RMS used in patients with symptomatic coronary artery disease. This registry follows the ESCEACTS guideline and observes RMS use in real-world settings without additional medical exclusion criteria beyond the devices intended instructions for use. The devices studied include Magmaris and Freesolve, both designed to improve the luminal diameter in the treatment of new native coronary artery lesions. The scaffold size is matched to the vessel diameter, and lesion length is limited to the scaffold length. The study collects data on these devices as they are used according to their approved instructions. Participants will be followed to assess the primary outcome of Target Lesion Failure within 12 months after device implantation. The registry collects clinical information during routine care to evaluate device performance and safety over time. The study started in November 2020 and will continue through May 2030.

Age: 18Years +All Genders
13 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the SELUTION SLR14 Drug Eluting Balloon DEB compared to plain uncoated balloon angioplasty in patients with peripheral arterial disease PAD affecting the below-the-knee BTK arteries, specifically in those with chronic limb-threatening ischemia CLTI. The study aims to show that the SELUTION SLR14 DEB has better efficacy and similar safety compared to the uncoated balloon treatment. Participants are adults aged 18 years or older with documented CLTI and significant narrowing in BTK arteries. The trial randomly assigns participants to one of two groups one receiving the SELUTION SLR14 DEB and the other receiving plain balloon angioplasty. Both are non-surgical procedures where a catheter inflates a balloon to open narrowed arteries below the knee. Treatments target specific lesions in BTK arteries and must meet detailed angiographic criteria. The study uses a single-blind design and includes follow-up assessments over several years. Participants will undergo evaluations at multiple time points including 30 days, 6 months, and up to 36 months after treatment. Assessments include clinical improvement, amputation rates, wound healing, imaging, and quality of life measures. Safety endpoints are monitored early, while efficacy outcomes are tracked long term. The study also evaluates device and procedural success immediately after treatment. Overall participation may last over three years to gather comprehensive safety and effectiveness data.

Age: 18Years +All GendersPhase Not Applicable
48 locations